Evolving Antibody Therapies for the Treatment of Type 1 Diabetes.
Evolving Antibody Therapies for the Treatment of Type 1 Diabetes.
复制标题
DOI：
10.3389/fimmu.2020.624568
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Tisch RM
中科院分区：
文献类型：
--
作者：
Ke Q;Kroger CJ;Clark M;Tisch RM
1 型糖尿病 (T1D) 被广泛认为是一种 T 细胞驱动的自身免疫性疾病，由于胰腺 β 细胞功能障碍/破坏，导致胰岛素产生减少。目前，临床上仍然需要选择性重建持续性β细胞特异性自我耐受的免疫疗法，以预防和缓解T1D。使用单克隆抗体 (mAb) 是针对诱导自身免疫驱动病理的特定免疫细胞群的一种策略。多种单克隆抗体已被证明具有临床安全性，并且在调节自身免疫（包括 T1D）方面表现出不同程度的功效。传统上，无论抗原特异性如何，单克隆抗体疗法都用于清除目标细胞群。然而，这种治疗策略可能是有害的，导致获得性保护性免疫力的丧失。非消耗性单克隆抗体也已被应用于调节免疫效应细胞的功能。最近的研究已经开始定义与基于 mAb 的免疫疗法相关的新机制，这些机制改变了靶向效应细胞库的功能。这些结果表明，短期单克隆抗体疗法可能对恢复和维持自我耐受性具有持久作用。此外，操纵 mAb 特性的灵活性允许开发新策略，以通过单个 mAb 分子靶向多种抗原和/或递送治疗药物。在这里，我们讨论当前和未来潜在的 T1D 治疗策略以及 T 细胞介导的自身免疫。
Type 1 diabetes (T1D) is widely considered to be a T cell driven autoimmune disease resulting in reduced insulin production due to dysfunction/destruction of pancreatic β cells. Currently, there continues to be a need for immunotherapies that selectively reestablish persistent β cell-specific self-tolerance for the prevention and remission of T1D in the clinic. The utilization of monoclonal antibodies (mAb) is one strategy to target specific immune cell populations inducing autoimmune-driven pathology. Several mAb have proven to be clinically safe and exhibit varying degrees of efficacy in modulating autoimmunity, including T1D. Traditionally, mAb therapies have been used to deplete a targeted cell population regardless of antigenic specificity. However, this treatment strategy can prove detrimental resulting in the loss of acquired protective immunity. Nondepleting mAb have also been applied to modulate the function of immune effector cells. Recent studies have begun to define novel mechanisms associated with mAb-based immunotherapy that alter the function of targeted effector cell pools. These results suggest short course mAb therapies may have persistent effects for regaining and maintaining self-tolerance. Furthermore, the flexibility to manipulate mAb properties permits the development of novel strategies to target multiple antigens and/or deliver therapeutic drugs by a single mAb molecule. Here, we discuss current and potential future therapeutic mAb treatment strategies for T1D, and T cell-mediated autoimmunity.
一种新型的胰腺β细胞靶向双特异性抗体（BSAB）可以防止NOD小鼠中1型糖尿病的发展。
DOI：
10.1016/j.clim.2014.04.014
发表时间：
2014-07
期刊：
Clinical immunology (Orlando, Fla.)
影响因子：
--
作者：
Bhattacharya P;Fan J;Haddad C;Essani A;Gopisetty A;Elshabrawy HA;Vasu C;Prabhakar BS
通讯作者：
Prabhakar BS